Sanofi-backed T-Ther­a­peu­tics bags $59M in Se­ries A to un­lock po­ten­tial of TCR ther­a­peu­tics: #Jef­feries23

LON­DON — T-Ther­a­peu­tics has raised £48 mil­lion ($59 mil­lion) in a Se­ries A round sup­port­ed by a Big Phar­ma in­vestor to dis­cov­er and de­vel­op new T cell re­cep­tor (TCR) ther­a­peu­tics us­ing its trans­genic mouse tech­nol­o­gy.

The round was co-led by Sofinno­va Part­ners, F-Prime Cap­i­tal, Dig­i­tal­is Ven­tures and Cam­bridge In­no­va­tion Cap­i­tal with con­tri­bu­tions from Sanofi Ven­tures and the Uni­ver­si­ty of Cam­bridge Ven­ture Fund. T-Ther­a­peu­tics will use the cash to ad­vance drugs for can­cer and in­flam­ma­to­ry dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER